These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 17536795

  • 21. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR.
    J Med Chem; 2003 Oct 09; 46(21):4405-18. PubMed ID: 14521405
    [Abstract] [Full Text] [Related]

  • 22. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
    Choi-Sledeski YM, McGarry DG, Green DM, Mason HJ, Becker MR, Davis RS, Ewing WR, Dankulich WP, Manetta VE, Morris RL, Spada AP, Cheney DL, Brown KD, Colussi DJ, Chu V, Heran CL, Morgan SR, Bentley RG, Leadley RJ, Maignan S, Guilloteau JP, Dunwiddie CT, Pauls HW.
    J Med Chem; 1999 Sep 09; 42(18):3572-87. PubMed ID: 10479289
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N, Kobayashi S, Komoriya S, Hirokawa Y, Furugori T, Nagahara T.
    Bioorg Med Chem Lett; 2004 Jun 07; 14(11):2935-9. PubMed ID: 15125963
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S, Kanaya N, Nagahara T, Yokoyama A, Inamura K, Yokoyama Y, Katakura S, Hara T.
    Bioorg Med Chem; 2004 May 01; 12(9):2099-114. PubMed ID: 15080912
    [Abstract] [Full Text] [Related]

  • 28. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Chung CW, Convery MA, Kelly HA, Paul King N, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):23-7. PubMed ID: 18054228
    [Abstract] [Full Text] [Related]

  • 29. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
    Imaeda Y, Miyawaki T, Sakamoto H, Itoh F, Konishi N, Hiroe K, Kawamura M, Tanaka T, Kubo K.
    Bioorg Med Chem; 2008 Mar 01; 16(5):2243-60. PubMed ID: 18077174
    [Abstract] [Full Text] [Related]

  • 30. Anthranilamide inhibitors of factor Xa.
    Mendel D, Marquart AL, Joseph S, Waid P, Yee YK, Tebbe AL, Ratz AM, Herron DK, Goodson T, Masters JJ, Franciskovich JB, Tinsley JM, Wiley MR, Weir LC, Kyle JA, Klimkowski VJ, Smith GF, Towner RD, Froelich LL, Buben J, Craft TJ.
    Bioorg Med Chem Lett; 2007 Sep 01; 17(17):4832-6. PubMed ID: 17624775
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR.
    J Med Chem; 2005 Mar 24; 48(6):1729-44. PubMed ID: 15771420
    [Abstract] [Full Text] [Related]

  • 33. Investigation of factor Xa inhibitors containing non-amidine S1 elements.
    Franciskovich JB, Masters JJ, Tinsley JM, Craft TJ, Froelich LL, Gifford-Moore DS, Klimkowski VJ, Smallwood JK, Smith GF, Smith T, Towner RR, Weir LC, Wiley MR.
    Bioorg Med Chem Lett; 2005 Nov 01; 15(21):4838-41. PubMed ID: 16140530
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
    Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Isobe Y, Furugohri T, Kanno H.
    Bioorg Med Chem Lett; 2007 Aug 15; 17(16):4683-8. PubMed ID: 17555959
    [Abstract] [Full Text] [Related]

  • 36. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.
    Ueno H, Yokota K, Hoshi J, Yasue K, Hayashi M, Uchida I, Aisaka K, Hase Y, Katoh S, Cho H.
    Bioorg Med Chem Lett; 2005 Jan 03; 15(1):185-9. PubMed ID: 15582437
    [Abstract] [Full Text] [Related]

  • 37. Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa.
    Jiang L, Wang Q, Shen S, Xiao T, Li Y.
    Thromb Res; 2014 Mar 03; 133(3):501-6. PubMed ID: 24412029
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA, Needle SJ, Burns-Kurtis CL, Valocik RE, Koster PF, Amour AJ, Chan C, Brown D, Chaudry L, Zhou P, Patikis A, Patel C, Pateman AJ, Young RJ, Watson NS, Toomey JR.
    J Cardiovasc Pharmacol; 2008 Jul 03; 52(1):66-71. PubMed ID: 18645410
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.